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Re: Does Free Cell Area Influence the Outcome in
Carotid Artery Stenting?
P.A. Gaines
Sheffield Vascular Institute, Northern General Hospital, Fourth 4C Floor,
Herries Road, Sheffield S5 7AU, UKAs the volume of data increases it is natural that
clinicians should search to find variables that affect
the outcome of carotid artery stenting. Some have
already been identified. It is clear that adjunctive
drug therapy plays a major part in guaranteeing
success,1 as does training and experience.2 CAS is
a procedure heavily dependant upon well designed
medical devices and it is to be expected that questions
will be asked as to whether all stents are equal. The
hurdle for this commentator was whether the article
by Bosiers et al. cast any light upon that particular
issue. In addition, the paper once again raises aware-
ness of the appropriateness, or otherwise, of treating
asymptomatic patients with CAS.
The authors are to be congratulated in obtaining
independent neurological review of all their pa-
tients. However, whilst they are open to some of
the limitations of the study there are others which
include:
1. The definitions used for stroke are unusual and
will presumably affect the message. For example,
most clinicians would define a neurological event
lasting less than 24 h as a TIA and not include it
as a major outcome measure by calling it a minor
stroke. Presumably this was a tool of convenience
for the authors to increase the number of out-
come events they could include in the analysis.
Unfortunately this could well change message of
the study. If count is only made of death and major
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assessing outcome using these authors definitions,
the Prote´ge´ and Exponent stents become the devices
with best outcome (0% stroke and death), and
contrary to the message of the paper, have an
open cell design with large cell size. Again, contrary
to the conclusion of the paper, the NexStent has the
worst outcome (stroke and death 3.3%), even
though it has a closed stent design with small free
cell area (2.5e5 mm2).
2. In general truth is not counter-intuitive. If cell size
is important then I would have expected it to
demonstrate an effect on any plaque, accepting
that symptomatic plaque is possibly more friable
than asymptomatic plaque. No such overall differ-
ence in outcome however was observed in asymp-
tomatic patients, and indeed, a stent with small
cell area (NexStent) had the second worst outcome
in asymptomatic patients.
3. This reviewer has heard on many occasions at
sponsored meetings the authors detail how stent
selection should be tailored specifically to the indi-
vidual patient and therefore allocation of patients
to particular stent designs is far from random.
It is likely that the particulars of device may well
have an effect on outcome but this reader finds little
in the published paper to be convincing.
Of similar contention, this reader is unaware of
any published literature showing convincing long
term benefit to asymptomatic patients managed
with CAS. These authors have demonstrated a
procedural death and adverse neurological eventrved.
143rate of 2.25%, with some cohorts suffering a 13%
adverse event rate. Such a high procedural adverse
event rate would make it difficult to demonstrate
long term benefit. It remains my conviction that
health care monies directed at stroke prophylaxis
by either CAS or endarterectomy be better spent
identifying and treating symptomatic patients
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